Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. Veeda Clinical Research buys European CRO Heads for an undisclosed sum

Veeda Clinical Research buys European CRO Heads for an undisclosed sum

26 Mar 2024

Add as preferred source
Key Takeaways

Veeda’s acquisition of Heads expands global presence, enhances oncology capabilities, and opens access to diverse patient populations in India and Southeast Asia.

Veeda’s acquisition of Heads expands global presence, enhances oncology capabilities, and opens access to diverse patient populations in India and Southeast Asia.

Veeda Clinical Research Unlisted Shares

Veeda Clinical Research

-0.44%

Expert Analysis

Veeda Clinical Research buys European CRO Heads for an undisclosed sum.

Expert Analysis:

  • Veeda Acquires Heads: Veeda Clinical Research acquires Heads, a European CRO specializing in oncology trials, to strengthen its global market position.

  • Global Expansion and Expertise: Veeda expands into major regions, gaining expertise in late-stage oncology trials, while Heads gains access to Indian and Southeast Asian markets.

  • Heads' Global Presence and Expertise: Founded in 2010, Heads operates in 25 locations across Europe, North America, and Asia Pacific, adding oncology expertise to Veeda’s portfolio for comprehensive drug development services.

  • Expanded Therapeutic Opportunities: Heads gain access to India’s diverse patient population for trials in oncology, diabetes, hypertension, and more, enhancing Veeda’s CRO services globally.

  • CEO Statement on Acquisition: Mahesh Bhalgat, Group CEO of Veeda, States that the acquisition's role is enabling large-scale, multi-geography clinical trials and fostering innovative treatments.

  • Binoy Gardi on Integration: Binoy Gardi, Executive Vice Chairperson of Veeda, states that the opportunity to expand markets, leverage complementary capabilities, and add value to clients during integration.

Publisher:Business Standard